BTR-NTA: Applicant FAQs and Applicant Guide

1.Am I eligible to apply?

The BTR-NTA welcomes researchers developing any type of therapeutic for brain tumour patients (including delivery technologies and devices):

  • Both academic and industry researchers
  • At any stage of pre-clinical or clinical work (as long as lead compound identified)
  • With a paediatric or adult focus
  • Developing novel or repurposed therapeutics.
  • From anywhere in the world

BTR-NTA also welcome research groups who have a therapeutic for another indication, but are considering brain cancer as a new indication.

2.What sorts of guidance / feedback can I seek?

You can seek guidance on a range of issues including: preclinical study robustness, safety, clinical trial design, understanding and addressing regulatory requirements, and commercialisation.

3.How is the feedback report shared?

The feedback report is returned to you within 8 weeks of the In-Person Review Meeting.

We will only share the report with you (the applicant), unless you have given us permission to do otherwise.

If you share the report with funders or other organisations, you are required to share the full and unmodified version in order to reflect the complete opinions of the BTR-NTA committee.

A brief, non-confidential summary will be published on the BTR-NTA website to allow the public to see that reviews have taken place. This summary will be agreed on by you and the BTR-NTA committee.

4.How much does the BTR-NTA process cost?

The review process is free for academic / non-commercial applicants. A nominal sliding fee will be charged to industry applicants based on the size of the company.

Academic applicants will be asked to pay an administration fee to secure a place on this sought after programme.

You will be responsible for funding your own travel costs and accommodation to attend the meeting.

5.Is the process confidential?

To protect your intellectual property, the review process is conducted under a strict confidentiality agreement and all reviewers are assessed for conflicts of interest prior to every in-person meeting.

The names and institutions of the reviewers will be shared with you, so you can also identify if there will be a potential conflict of interest.

Any intellectual property produced during the review process remains with you.

Prior to submitting your full application form, you will sign an Applicant Agreement which outlines: the confidentiality and conflicts of interest process, your obligations when sharing the feedback report, as well as timelines etc.

6.Can I receive ongoing guidance and feedback following the BTR-NTA review?

The BTR-NTA review process is a one-off review and the committee will not provide ongoing guidance.

We welcome you to re-apply at a later date if your programme has progressed substantially.

7.Will I receive funding after the BTR-NTA review?

The BTR-NTA review process is independent of funders, and no funding will be awarded as part of the review.

The BTR-NTA feedback report can however be shared with funders, and may help you facilitate a funding application.

The BTR-NTA Committee may also recommend potential avenues for partnerships or funding as part of the review.

8.Will I receive a score or endorsement from the BTR-NTA Committee?

The feedback report will describe the strengths and potential pitfalls/risks of your work to date, provide guidance on next steps, and will aim to answer your questions.

No numerical score or endorsement will be given as part of the review.

The BTR-NTA review process is focused on being educational, and does not assign any status in terms of funding or regulatory potential.

The BTR-NTA review will not grade the quality of the therapeutic.


For further information, please refer to the BTR-NTA Applicant Guide